• Phelps Holland posted an update 6 months, 3 weeks ago

    08 ± 0.04 mm) than in the normal axial length group (0.09 ± 0.05 mm) during the 3 months after surgery (

    = .036).

    The position of the IOL was almost stable 1 month after operation, and postoperative capsule adhesion mainly occurred within 1 month. The change in PAD was related to capsule adhesion. The postoperative position of the IOL was relatively stable and capsular bend was relatively slow for the long axial length group over 3 months.

    .

    The position of the IOL was almost stable 1 month after operation, and postoperative capsule adhesion mainly occurred within 1 month. The change in PAD was related to capsule adhesion. The postoperative position of the IOL was relatively stable and capsular bend was relatively slow for the long axial length group over 3 months. .

    To establish a simple clinical method of predicting addition power achieved with a multifocal intraocular lens (IOL).

    In this prospective cohort study, 41 patients were bilaterally implanted with the Bi-Flex MY multifocal IOL (Medicontur) with +3.50 diopters (D) near addition power. Monocular defocus curves were plotted for each patient and effective addition power was calculated as the dioptric difference between the distance and near inflection points of the defocus curve. Six biometry formulas (Haigis, Holladay, SRK/T, Hill RBF, Barrett Universal II, and Holladay 2) were used to predict the addition power at the spectacle plane.

    Mean effective addition power was 2.60 ± 0.29 D, with significant (

    < .01) differences between the prediction methods. Significant differences were found between predicted and effective addition when the Holladay, SRK/T, Hill RBF, and Holladay 2 formulas were used. A moderate but significant correlation (

    = 0.342,

    = .033) was found with the Barrett formula, and this was also the method to show the least proportional bias with Bland-Altman analysis.

    The study demonstrates that the effective addition power can be predicted using the proposed simple clinical method derived using the Barrett Universal II formula. The proposed technique may have significant clinical value in screening for patients where ocular biometry may lead to aberrant addition power.

    .

    The study demonstrates that the effective addition power can be predicted using the proposed simple clinical method derived using the Barrett Universal II formula. The proposed technique may have significant clinical value in screening for patients where ocular biometry may lead to aberrant addition power. .

    To evaluate refractive and visual outcomes of small incision guided human cornea treatment (SmartSight; SCHWIND eye-tech-solutions) in the treatment of myopic astigmatism with the use of a new femtosecond laser system.

    This retrospective, observational case series study included 104 eyes of 56 patients who underwent SmartSight to correct myopic astigmatism and completed the 3-month follow-up. see more Procedures were performed with a SCHWIND ATOS femtosecond laser.

    Preoperatively, mean manifest spherical equivalent refraction was -6.12 ± 1.99 diopters (D) (range -3.00 to -11.50 D) and astigmatism was 1.02 ± 0.56 D (range 0.25 to 2.75 D). Three months postoperatively, it was +0.47 ± 0.32 D (range -0.75 to +1.00 D) and 0.27± 0.22 D (range 0.00 to 0.75 D), respectively (both

    < .05). Spherical equivalent correction within ±0.50 D was achieved in 62 eyes (60%), and cylindrical correction in 90 eyes (87%). Preoperative corrected distance visual acuity (CDVA) was 20/20 or better in 94 eyes (90%) and postoperative uncorrected distance visual acuity was 20/20 or better in 96 eyes (92%). No eye lost two or more Snellen lines of CDVA.

    Myopic astigmatism correction with Smart-Sight provided good results for efficacy, safety, predictability, and visual outcomes in the first 3 months of follow-up.

    .

    Myopic astigmatism correction with Smart-Sight provided good results for efficacy, safety, predictability, and visual outcomes in the first 3 months of follow-up. .

    To assess the long-term efficacy and safety of epithelium-off corneal cross-linking according to the standard (Dresden) protocol (S-CXL) in patients with progressive keratoconus older than 40 years.

    Seventy-six eyes of 64 patients with a mean age of 46.4 ± 5.2 years were included. At baseline and after 6, 12, 24, 36, 48, 60, 72, 84, and more than 96 months (when available) after S-CXL, all patients were assessed with distance-corrected visual acuity (DCVA) and corneal topography and tomography with Pentacam HR (OCULUS Optikgeräte GmbH). A generalized linear model was used to compare the groups. Outcome measures were maximum keratometry, thinnest point, coma, spherical, and higher order aberrations, and ABC values. Fixed and random factors were age, gender, atopy, laterality, and group.

    The mean follow-up time was 62.1 ± 40.1 months (range 12 to 144 months). The main outcome of the study was the evidence that S-CXL was able to safely stop the progression of keratoconus in all patients with none requiring repeat CXL. The generalized linear model analysis showed no significant change in DCVA over time (

    = 1.000), but atopy was negatively associated with DCVA (

    = .030, B = -0.69). The generalized linear model also showed that CXL was able to induce a significant flattening demonstrated as reduction of maximum keratometry (

    = .001, B = -0.35) and A value (

    =.001, B = -0.015) of the ABC display. Similarly, coma aberration was reduced over time (

    = .006, B = -0.005).

    S-CXL was confirmed to be a safe and effective treatment for progressive keratoconus even after the age of 40 years, inducing a significant flattening of the cone.

    .

    S-CXL was confirmed to be a safe and effective treatment for progressive keratoconus even after the age of 40 years, inducing a significant flattening of the cone. .

    To assess enlargement of the clear corneal incision site and functional outcome in patients with cataract, following the use of two preloaded intraocular lens (IOL) injectors.

    In this prospective, randomized, intraindividual comparative clinical study, 58 paired-eyes were randomly assigned for implantation with two preloaded injectors AutonoMe with a Clareon IOL (Alcon Laboratories, Inc) and iSert with a Vivinex IOL (Hoya). The size of the corneal incision, 2 mm for the iSert and 2.2 mm for the AutonoMe, was measured before and after phacoemulsification and after IOL implantation. Patients were examined 3 months after surgery to assess keratometry, subjective refraction, and visual acuity.

    The incision enlargement was 0.20 ± 0.10 mm for the AutonoMe and 0.29 ± 0.10 mm for the iSert, with a statistically significant difference (

    < .05). The final wound size after IOL implantation was 2.41 mm for the AutonoMe and 2.35 mm for the iSert. The mean absolute surgically induced astigmatism (SIA) was 0.50 ± 0.

All content contained on CatsWannaBeCats.Com, unless otherwise acknowledged,is the property of CatsWannaBeCats.Com and subject to copyright.

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account